All In Biotech

Drug Trial Radar · NCT00430495

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)

A Randomized, Double-blind, Placebo-controlled, Multicentre, Phase II Dose-finding Study of Atacicept Given Subcutaneously in Subjects With Rheumatoid Arthritis and Inadequate Response to TNFa Antagonist Therapy

Last checked: Nov 20, 2026Latest source record: Feb 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 256 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

256

Actual

Start

Dec 2006

Primary completion

Sep 2009

Study completion Sep 2009

Sponsor

Lead sponsor
EMD SeronoIndustry
Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Feb 2, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a double-blind, placebo-controlled, parallel-arm, multicentre, prospective dose-finding trial of the safety and efficacy of atacicept in subjects with active rheumatoid arthritis who had failed a three month therapeutic trial with a tumor necrosis factor alpha (TNFa) antagonist due to lack of efficacy.

Conditions

  • Rheumatoid Arthritis

Interventions

  • AtaciceptDrug

    Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.

  • AtaciceptDrug

    Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.

  • AtaciceptDrug

    Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.

  • Placebo matched to ataciceptDrug

    Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26Time frame: Week 26

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • EMD Serono

    Rockland, Massachusetts

  • Merck/Serono

    Canada, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.